Philip Astley-Sparke

Philip Astley-Sparke

DirectoratReplimune Group· In proxies 2022–2025

Pay in FY2024+65% from the year before · Replimune Group stock -53.7% the same year

Philip Astley-Sparke was paid $6.0M in FY2024 (Mar), up 65%. Replimune Group stock fell 53.7% that year.

Pay$100 in the stock at the end of FY21 → $27
Pay is from the Summary Compensation Table of each Replimune Group proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. enGene TherapeuticsPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  2. Replimune GroupPublic company · 4 yr
    • Chair of the Board2022 – Present · 4 yrStock in role -47%
  3. Synox Therapeutics Ltd.Public company
    • Director? – PresentNo stock prices for these years
  4. Forbion European Acquisition Corp.Public company · 5 yr
    • Director2021 – Present · 5 yrNo stock prices for these years
  5. Oxyrane LimitedPublic company · 8 yr
    • Director2012 – 2020 · 8 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?